ABG
CNTX icon

Ally Bridge Group’s Context Therapeutics CNTX Stock Holding History

Ally Bridge Group’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,157,448
Closed -$708K – 29
2025
Q1 		$708K Sell
1,157,448
-419,314
-27% -$365K 0.64% 28
2024
Q4 		$1.66M Sell
1,576,762
-180,762
-10% -$313K 1.42% 28
2024
Q3 		$3.44M Sell
1,757,524
-128,708
-7% -$286K 1.84% 28
2024
Q2 		$3.78M Buy
1,886,232
+1,160,281
+160% +$2M 2.25% 23
2024
Q1 		$1M Hold
725,951
– – 0.56% 22
2023
Q4 		$820K Hold
725,951
– – 0.49% 21
2023
Q3 		$1.1M Buy
725,951
+72,555
+11% +$82.1K 1.29% 17
2023
Q2 		$1.05M Buy
+653,396
New +$556K 1.27% 16

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Ally Bridge Group's CNTX Position: Q2 2025 in Review

Ally Bridge Group sold out of Context Therapeutics (CNTX) in Q2 2025, closing a stake of 1,157,448 shares — an estimated $708K sold.

Ally Bridge Group first reported a position in CNTX in Q2 2023 and held it in 8 quarters. The position peaked at $3.78M in Q2 2024. 39 funds tracked by Wall St. Rank hold CNTX as of Q2 2025.

  • Ally Bridge Group reported no remaining Context Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ally Bridge Group sold 1,157,448 Context Therapeutics shares in Q2 2025, an estimated $708K.
  • Ally Bridge Group first reported a position in Context Therapeutics in Q2 2023 and held it in 8 quarters.
  • Ally Bridge Group's Context Therapeutics position peaked at $3.78M in Q2 2024.
  • 39 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2025.

Based on Ally Bridge Group's 13F filing for Q2 2025, filed 14 Aug 2025.